AVE1231 | CAS#767334-89-4 | Kv1.5 Inhibitor

MedKoo Cat#: 564461 | Name: AVE1231

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AVE1231 is an atrial-selective antiarrhythmic human cardiac Kv1.5 inhibitor.

Chemical Structure

AVE1231

CAS#767334-89-4

Theoretical Analysis

MedKoo Cat#: 564461

Name: AVE1231

CAS#: 767334-89-4

Chemical Formula: C20H27N3O4S

Exact Mass: 405.1722

Molecular Weight: 405.51

Elemental Analysis: C, 59.24; H, 6.71; N, 10.36; O, 15.78; S, 7.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

A-293; A 293; A293; AVE-1231; AVE 1231; AVE1231

IUPAC/Chemical Name

(R)-2-(Butylsulfonamido)-N-(1-(6-methoxypyridin-3-yl)propyl)benzamide

InChi Key

BFQMQSIBOHOPCY-QGZVFWFLSA-N

InChi Code

InChI=1S/C20H27N3O4S/c1-4-6-13-28(25,26)23-18-10-8-7-9-16(18)20(24)22-17(5-2)15-11-12-19(27-3)21-14-15/h7-12,14,17,23H,4-6,13H2,1-3H3,(H,22,24)/t17-/m1/s1

SMILES Code

O=C(N[C@@H](C1=CC=C(OC)N=C1)CC)C2=CC=CC=C2NS(=O)(CCCC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 405.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Thörn Pérez C, Hill RH, Grillner S. Substance P Depolarizes Lamprey Spinal Cord Neurons by Inhibiting Background Potassium Channels. PLoS One. 2015 Jul 21;10(7):e0133136. doi: 10.1371/journal.pone.0133136. eCollection 2015. PubMed PMID: 26197458; PubMed Central PMCID: PMC4510128. 2: Kiper AK, Rinné S, Rolfes C, Ramírez D, Seebohm G, Netter MF, González W, Decher N. Kv1.5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea? Pflugers Arch. 2015 May;467(5):1081-90. doi: 10.1007/s00424-014-1665-1. Epub 2014 Dec 17. PubMed PMID: 25511502. 3: Ehrlich JR, Ocholla H, Ziemek D, Rütten H, Hohnloser SH, Gögelein H. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol. 2008 Apr;51(4):380-7. doi: 10.1097/FJC.0b013e3181669030. PubMed PMID: 18427281. 4: Wirth KJ, Brendel J, Steinmeyer K, Linz DK, Rütten H, Gögelein H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol. 2007 Apr;49(4):197-206. PubMed PMID: 17438404.